

# Special Bulletin

July 2007

---

## Tykerb and Zolinza Being Added to Program for Self-Administered Injectable or Oral Biotechnology Drugs, Effective Aug. 6, 2007

Effective Aug. 6, 2007, Tykerb (lapatinib) and Zolinza (vorinostat) will be added to Highmark Blue Shield's special program for self-administered injectable or oral biotechnology specialty drugs. Members who use Tykerb or Zolinza will need to obtain it exclusively from Medmark. Tykerb and Zolinza will no longer be covered if obtained at a retail pharmacy or via mail order service.

For more information about this program, please refer to the Special Bulletin dated Jan. 4, 2006, titled "New Program for Self-Administered Injectable or Oral Biotechnology Drugs." You can also find this Special Bulletin on the Provider Resource Center on NaviNet<sup>®</sup> and at [www.highmarkblueshield.com](http://www.highmarkblueshield.com). Hover on *Publications & Mailings* and select *Special Bulletins & Mailings*. You'll find it under the *Formulary/Drug* link.

### Simplified Precertification Process

There are no changes to medical policy or procedures. Members whose benefit designs currently require precertification for Tykerb or Zolinza will continue to require precertification. It remains the physician's responsibility to obtain precertification.

Physicians can simply make one telephone call to Medmark at 1-888-347-3416 to initiate the precertification process and to order Tykerb or Zolinza for your patients. Through this simplified procedure, physicians save time and members receive these medications promptly and directly at their home.

This program can be used for all Highmark Blue Shield patients. Due to the new Medicare Part D prescription drug coverage regulations, the program is not mandatory for Medicare Advantage (FreedomBlue<sup>SM</sup>) patients. However, Medicare Advantage patients still have the option to obtain their specialty drugs through Medmark.

In addition to calling Medmark, physicians can continue to use the *Specialty Drug Request Form*, which can be found in the *Provider Forms* section on our Provider Resource Center at [www.highmarkblueshield.com](http://www.highmarkblueshield.com).

If you have specific questions about Highmark Blue Shield's special program for self-administered injectable or oral biotechnology specialty drugs, please contact Provider Service at 1-800-731-8080 (Central Region), 1-800-975-7290 (Eastern Region) and 1-866-262-5635 (Northeastern Region).

FreedomBlue is a service mark of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. NaviNet is a registered trademark of NaviMedix, Inc.



An Independent Licensee of the Blue Cross and Blue Shield Association

Camp Hill, PA 17089